- New
-
Topics
- All Categories
- Metaphysics and Epistemology
- Value Theory
- Science, Logic, and Mathematics
- Science, Logic, and Mathematics
- Logic and Philosophy of Logic
- Philosophy of Biology
- Philosophy of Cognitive Science
- Philosophy of Computing and Information
- Philosophy of Mathematics
- Philosophy of Physical Science
- Philosophy of Social Science
- Philosophy of Probability
- General Philosophy of Science
- Philosophy of Science, Misc
- History of Western Philosophy
- Philosophical Traditions
- Philosophy, Misc
- Other Academic Areas
- Journals
- Submit material
- More
The Role of Controversial Research in the IRB's Risk/Benefit Analysis
American Journal of Bioethics 11 (5):14-16 (2011)
Abstract
This article has no associated abstract. (fix it)My notes
Similar books and articles
Exempting All Minimal-Risk Research from IRB Review: Pruning or Poisoning the Regulatory Tree?Mahesh Ananth & Mike Scheessele - 2012 - IRB: Ethics & Human Research 34 (2):9-14.
Conflicting interests, social justice and proxy consent to research.Daryl Pullman - 2002 - Journal of Medicine and Philosophy 27 (5):523 – 545.
Conflict and convergence: The ethics review of action research. [REVIEW]Michael Owen - 2006 - Journal of Academic Ethics 4 (1-4):61-75.
Science, democracy, and public policy.Kristin Shrader-Frechette - 1992 - Critical Review: A Journal of Politics and Society 6 (2):255-264.
Making Risk-Benefit Assessments of Medical Research Protocols.Alex Rajczi - 2004 - Journal of Law, Medicine and Ethics 32 (2):338-348.
Understanding risks and benefits in research on reproductive genetic technologies.Janet Malek - 2007 - Journal of Medicine and Philosophy 32 (4):339 – 358.
Risk-Benefit Analysis: From a Logical Point of View. [REVIEW]Georg Spielthenner - 2012 - Journal of Bioethical Inquiry 9 (2):161-170.
Economics, Risk-Cost-Benefit Analysis, and the Linearity Assumption.K. S. Shrader-Frechette - 1982 - PSA: Proceedings of the Biennial Meeting of the Philosophy of Science Association 1982:217 - 232.
The harm-benefit tradeoff in "bad deal" trials.Gillian Nycum & Lynette Reid - 2007 - Kennedy Institute of Ethics Journal 17 (4):321-350.
Are Phase 1 Trials Therapeutic? Risk, Ethics, and Division of Labor.James A. Anderson & Jonathan Kimmelman - 2012 - Bioethics 28 (3):138-146.
Human participants challenges in youth-focused research: Perspectives and practices of IRB administrators.Diane K. Wagener, Amy K. Sporer, Mary Simmerling, Jennifer L. Flome, Christina An & Susan J. Curry - 2004 - Ethics and Behavior 14 (4):335 – 349.
Ethical aspects of vulnerability in research.Elisabeth Weisser-Lohmann - 2012 - Poiesis and Praxis 9 (1-2):157-162.
Analytics
Added to PP
2011-05-01
Downloads
23 (#687,700)
6 months
5 (#649,144)
2011-05-01
Downloads
23 (#687,700)
6 months
5 (#649,144)
Historical graph of downloads
Citations of this work
An Argument for Fewer Clinical Trials.Kirstin Borgerson - 2016 - Hastings Center Report 46 (6):25-35.
Consideration and Disclosure of Group Risks in Genomics and Other Data-Centric Research: Does the Common Rule Need Revision?Carolyn Riley Chapman, Gwendolyn P. Quinn, Heini M. Natri, Courtney Berrios, Patrick Dwyer, Kellie Owens, Síofra Heraty & Arthur L. Caplan - forthcoming - American Journal of Bioethics:1-14.
References found in this work
Dealing With the Long-Term Social Implications of Research.Jeremy Sugarman, Dale E. Hammerschmidt, Christine Grady, Lisa Eckenwiler, Carol Levine & Alan Fleischman - 2011 - American Journal of Bioethics 11 (5):5-9.
Power and Representation of the Public's Values in a Social Implications of Research Commission.John H. Evans - 2011 - American Journal of Bioethics 11 (5):10-11.
PhilPapers logo by Andrea Andrews and Meghan Driscoll.
This site uses cookies and Google Analytics (see our terms & conditions for details regarding the privacy implications). Use of this site is subject to terms & conditions.
All rights reserved by The PhilPapers Foundation
Server: philpapers-web-7c88c7cdf7-8qzwx uwo